p.96 抽出テキスト

758. Mills JL Sr, Conte MS, Armstrong DG, Pomposelli FB, Schanzer A, Sidawy AN, et al. The society for vascular surgery lower extremity threatened limb classification system: risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg 2014; 59:220–234. https://doi.org/10.1016/j.jvs.2013.08.003 759. Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J 2014;35:2873–2926. https://doi.org/10. 1093/eurheartj/ehu281 760. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res 2015;116: 1509–1526. https://doi.org/10.1161/CIRCRESAHA.116.303849 761. Hinchliffe RJ, Forsythe RO, Apelqvist J, Boyko EJ, Fitridge R, Hong JP, et al. Guidelines on diagnosis, prognosis, and management of peripheral artery disease in patients with foot ulcers and diabetes (IWGDF 2019 update). Diabetes/Metab Res Rev 2020;36: e3276. https://doi.org/10.1002/dmrr.3276 762. Tehan PE, Barwick AL, Sebastian M, Chuter VH. Diagnostic accuracy of the postexercise ankle–brachial index for detecting peripheral artery disease in suspected claudicants with and without diabetes. Vasc Med 2018;23:116–125. https://doi.org/10. 1177/1358863X17751259 763. Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, Diehm C, et al. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation 2012;126:2890–2909. https://doi. org/10.1161/CIR.0b013e318276fbcb 764. Verma S, Al-Omran M, Leiter LA, Mazer CD, Rasmussen S, Saevereid HA, et al. Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease. Diabetes Obes Metab 2022;24:1288–1299. https://doi.org/ 10.1111/dom.14700 765. Verma S, Mazer CD, Al-Omran M, Inzucchi SE, Fitchett D, Hehnke U, et al. Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME. Circulation 2018;137:405–407. https://doi.org/10.1161/CIRCULATIONAHA.117. 032031 766. Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018;391: 219–229. https://doi.org/10.1016/S0140-6736(17)32409-1 767. Anand SS, Caron F, Eikelboom JW, Bosch J, Dyal L, Aboyans V, et al. Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial. J Am College Cardiol 2018;71:2306–2315. https://doi.org/10.1016/j.jacc.2018.03.008 768. Hinchliffe RJ, Brownrigg J, Andros G, Apelqvist J, Boyko EJ, Fitridge R, et al. Effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral artery disease: a systematic review. Diabetes Metab Res Rev 2016;32:136–144. https://doi. org/10.1002/dmrr.2705 769. Venermo M, Sprynger M, Desormais I, Björck M, Brodmann M, Cohnert T, et al. Follow-up of patients after revascularisation for peripheral arterial diseases: a consensus document from the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases and the European Society for Vascular Surgery. Eur J Prev Cardiol 2019;26:1971–1984. https://doi.org/10.1177/2047487319846999 770. Wu T-W, Chou C-L, Cheng C-F, Lu S-X, Wang L-Y. Prevalences of diabetes mellitus and carotid atherosclerosis and their relationships in middle-aged adults and elders: a community-based study. J Formosan Med Assoc 2021;121:1133–1140. https://doi.org/ 10.1016/j.jfma.2021.10.005 771. Lacroix P, Aboyans V, Criqui M, Bertin F, Bouhamed T, Archambeaud F, et al. Type-2 diabetes and carotid stenosis: a proposal for a screening strategy in asymptomatic patients. Vasc Med 2006;11:93–99. https://doi.org/10.1191/1358863(06vm677oa 772. Weyer GW, Davis AM. Screening for asymptomatic carotid artery stenosis. JAMA 2015;313:192–194. https://doi.org/10.1001/jama.2014.16804 773. Hussain MA, Bin-Ayeed SA, Saeed OQ, Verma S, Al-Omran M. Impact of diabetes on carotid artery revascularization. J Vasc Surg 2016;63:1099–1107. https://doi.org/10. 1016/j.jvs.2015.12.041 774. Lal BK, Beach KW, Roubin GS, Lutsep HL, Moore WS, Malas MB, et al. Restenosis after carotid artery stenting and endarterectomy: a secondary analysis of CREST, a randomised controlled trial. Lancet Neurol 2012;11:755–763. https://doi.org/10.1016/S1474- 4422(12)70159-X 775. Pafili K, Gouni-Berthold I, Papanas N, Mikhailidis DP. Abdominal aortic aneurysms and diabetes mellitus. J Diabetes Complications 2015;29:1330–1336. https://doi.org/10. 1016/j.jdiacomp.2015.08.011 776. Nikol S, Mathias K, Olinic DM, Blinc A, Espinola-Klein C. Aneurysms and dissections – what is new in the literature of 2019/2020 – a European Society of Vascular Medicine annual review. Vasa 2020;49:1–36. https://doi.org/10.1024/0301-1526/a000865 777. Dattani N, Sayers RD, Bown MJ. Diabetes mellitus and abdominal aortic aneurysms: a review of the mechanisms underlying the negative relationship. Diab Vasc Dis Res 2018; 15:367–374. https://doi.org/10.1177/1479164118780799 778. Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation 2018;137:338–350. https://doi.org/10.1161/ CIRCULATIONAHA.117.032235 779. Jukema JW, Szarek M, Zijlstra LE, de Silva HA, Bhatt DL, Bittner VA, et al. Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial. J Am College Cardiol 2019;74:1167–1176. https://doi.org/10.1016/ j.jacc.2019.03.013 780. Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK. Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care 2015;38:316–322. https://doi.org/ 10.2337/dc14-0920 781. Vergès B. Cardiovascular disease in type 1 diabetes: a review of epidemiological data and underlying mechanisms. Diabetes Metab 2020;46:442–449. https://doi.org/10. 1016/j.diabet.2020.09.001 782. Jørgensen ME, Almdal TP, Carstensen B. Time trends in mortality rates in type 1 diabetes from 2002 to 2011. Diabetologia 2013;56:2401–2404. https://doi.org/10.1007/ s00125-013-3025-7 783. Livingstone SJ, Looker HC, Hothersall EJ, Wild SH, Lindsay RS, Chalmers J, et al. Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS One 2012;9:e1001321. https://doi.org/10.1371/journal.pmed. 1001321 784. Lind M, Svensson A-M, Rosengren A. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med 2015;372:880–881. https://doi.org/10.1056/nejmc1415677 785. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643–2653. https://doi.org/10.1056/NEJMoa052187 786. Zinman B, Genuth S, Nathan DM. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study: 30th anniversary presentations. Diabetes Care 2014;37:8. https://doi.org/10.2337/dc13-2111 787. Bebu I, Braffett BH, Orchard TJ, Lorenzi GM, Lachin JM, DCCT/EDIC Research Group. Mediation of the effect of glycemia on the risk of CVD outcomes in type 1 diabetes: the DCCT/EDIC study. Diabetes Care 2019;42:1284–1289. https://doi.org/10.2337/dc18- 1613 788. Rawshani A, Rawshani A, Sattar N, Franzén S, McGuire DK, Eliasson B, et al. Relative prognostic importance and optimal levels of risk factors for mortality and cardiovascular outcomes in type 1 diabetes mellitus. Circulation 2019;139:1900–1912. https:// doi.org/10.1161/CIRCULATIONAHA.118.037454 789. Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Gudbjörnsdottir S; Swedish National Diabetes Register. A new model for 5-year risk of cardiovascular disease in Type 1 diabetes; from the Swedish National Diabetes Register (NDR). Diabet Med 2011;28:1213–1220. https://doi.org/10.1111/j.1464-5491.2011.03342.x 790. Vistisen D, Andersen GS, Hansen CS, Hulman A, Henriksen JE, Bech-Nielsen H, et al. Prediction of first cardiovascular disease event in type 1 diabetes mellitus: the Steno Type 1 Risk Engine. Circulation 2016;133:1058–1066. https://doi.org/10.1161/ CIRCULATIONAHA.115.018844 791. Rawshani A, Sattar N, Franzén S, Rawshani A, Hattersley AT, Svensson A-M, et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet 2018;392: 477–486. https://doi.org/10.1016/S0140-6736(18)31506-X 792. Miller RG, Costacou T, Orchard TJ. Risk factor modeling for cardiovascular disease in type 1 diabetes in the Pittsburgh epidemiology of diabetes complications (EDC) study: a comparison with the diabetes control and complications trial/epidemiology of diabetes interventions and complications study (DCCT/EDIC). Diabetes 2019;68: 409–419. https://doi.org/10.2337/db18-0515 793. McGurnaghan SJ, McKeigue PM, Read SH, Franzen S, Svensson A-M, Colombo M, et al. Development and validation of a cardiovascular risk prediction model in type 1 diabetes. Diabetologia 2021;64:2001–2011. https://doi.org/10.1007/s00125-021-05478-4 794. Teoh I, Elisaus P, Schofield J. Cardiovascular risk management in type 1 diabetes. Curr Diabetes Rep 2021;21:29. https://doi.org/10.1007/s11892-021-01400-9 795. Wu N, Bredin SS, Guan Y, Dickinson K, Kim DD, Chua Z, et al. Cardiovascular health benefits of exercise training in persons living with type 1 diabetes: a systematic review and meta-analysis. J Clin Med 2019;8:253. https://doi.org/10.3390/jcm8020253 796. Ciriacks K, Coly G, Krishnaswami S, Patel SB, Kidambi S. Effects of simvastatin and ezetimibe in lowering low-density lipoprotein cholesterol in subjects with type 1 and type 2 diabetes mellitus. Metab Syndr Relat Disord 2015;13:84–90. https://doi.org/10.1089/ met.2014.0114 797. Tell S, Nadeau KJ, Eckel RH. Lipid management for cardiovascular risk reduction in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 2020;27:207. https://doi.org/10.1097/ MED.0000000000000551 798. Guo J, Brooks MM, Muldoon MF, Naimi AI, Orchard TJ, Costacou T. Optimal blood pressure thresholds for minimal coronary artery disease risk in type 1 diabetes. Diabetes Care 2019;42:1692–1699. https://doi.org/10.2337/dc19-0480 799. Lithovius R, Gordin D, Forsblom C, Saraheimo M, Harjutsalo V, Groop P-H; FinnDiane Study Group. Ambulatory blood pressure and arterial stiffness in individuals with type Downloaded from academic.oup.com/eurheartj/article/44/39/4043/7238227 by guest on 07 October 2026